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Abstract
Background: This paper presents qualitative findings from an assessment of the acceptability of
using economic evaluation among policy actors in Thailand. Using cost-utility data from two
economic analyses a hypothetical case scenario was created in which policy actors had to choose
between two competing interventions to include in a public health benefit package. The two
competing interventions, laparoscopic cholecystectomy (LC) for gallbladder disease versus renal
dialysis for chronic renal disease, were selected because they highlighted conflicting criteria
influencing the allocation of healthcare resources.
Methods: Semi-structured interviews were conducted with 36 policy actors who play a major role
in resource allocation decisions within the Thai healthcare system. These included 14 policy makers
at the national level, five hospital directors, ten health professionals and seven academics.
Results: Twenty six out of 36 (72%) respondents were not convinced by the presentation of
economic evaluation findings and chose not to support the inclusion of a proven cost-effective
intervention (LC) in the benefit package due to ethical, institutional and political considerations.
There were only six respondents, including three policy makers at national level, one hospital
director, one health professional and one academic, (6/36, 17%) whose decisions were influenced
by economic evaluation evidence.
Conclusion: This paper illustrates limitations of using economic evaluation information in decision
making priorities of health care, perceived by different policy actors. It demonstrates that the
concept of maximising health utility fails to recognise other important societal values in making
health resource allocation decisions.
Background
In all societies health care resources are restricted so that
priority setting for health expenditure has to be done
either implicitly or explicitly[1]. Health economic evalua-
tion is a method used to analyse the costs and benefits of
different health care interventions, and has often been
quoted as the most promising tool to assist decision-mak-
ers in health care rationing[2,3]. Cost-utility analysis,
which is one type of health economic evaluation, is
widely recommended in many official health technology
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assessment guidelines in many settings [4-7]. The method
assumes that the ultimate goal of the health care system is
to maximise health benefits from the finite resources
available, regardless of the distribution of these health
benefits. To allow comparisons across a broad spectrum
of intervention or programme areas, a common health
benefit composite indicator, such as the Quality Adjusted
Life Year (QALY), has been created and applied to numer-
ous interventions to enable decision makers to decide
which health investments maximise health (QALYs)[8,9].
A QALY measures both the quantity of life generated by an
intervention (in years) and the change to quality of life in
each of those years.
Although there are several moral and methodological
controversies over the use of economic evaluation to
guide health resource allocation[3,10,11], it is increas-
ingly being used in some industrial countries on the
grounds that it can inform more explicit and transparent
health care coverage decisions[12]. In low- and middle-
income countries the tool has rarely been used to inform
decisions about the content of health care benefit pack-
ages. However in middle income countries such as Thai-
land policy-makers are facing growing pressure to justify
resource allocation decisions in the health sector, due to
increasing resource constraints arising from an epidemio-
logical transition and increases in the availability and cost
of new health technologies [13-15]. In Thailand the Uni-
versal Health Insurance Coverage (UC) policy imple-
mented in 2001 offers a package of health care
interventions at public facilities to all Thai citizens not
covered by other benefit packages[16]. There is growing
pressure on the government to clarify and make more
transparent the UC benefit package, particularly for high
cost interventions that absorb a disproportionate amount
of resources[17]. Some high cost interventions are
included in the package, others are excluded and some are
in a 'grey zone' and provided at the discretion of consult-
ants or hospital directors. A mix of criteria, mainly
implicit, have influenced these decisions, for example pre-
existing service availability, affordability for the provider
and political pressures[18].
This paper presents qualitative findings based on semi-
structured face-to-face interviews that explored the accept-
ability of using only evidence from economic evaluation
among different policy actors. A case scenario was con-
structed using information from two separate economic
evaluation studies previously conducted in Thailand. One
was an economic evaluation of open versus laparoscopic
cholecystectomy for gallbladder stone disease[19] and the
other was an economic evaluation of renal dialysis com-
pared to palliative treatment of end-stage renal dis-
ease[20]. The interviews sought to explore policy actors'
justifications for their decisions on the case scenarios,
including the trade-offs they had to make between cost
utility criteria founded on the principle of health (QALY)
maximisation, and other criteria such as disease severity
and overall budget impact[21,22].
Methods
Respondents
The selection of respondents was purposive to cover four
groups of policy actors who play a major role or influence
in health resource allocation decisions within the Thai
healthcare system. A purposive sampling strategy was
used to ensure that a range of policy actors was covered
and that, at the highest level, the most important policy
actors were selected. The qualitative data generated is not
intended to be 'representative' in statistical terms, but the
data can be used to build understanding of policy actors'
attitudes and positions relating to economic evaluation in
decision-making. Depth of understanding rather than
sample size was the main concern[23,24]. However the
policy relevance of the findings did rely on ensuring that
an appropriate range of policy actors for this particular
setting were covered, to enable the capture of a 'typical'
range of perspectives[25].
As a result, an invitation letter, research proposal and con-
sent form were sent to each of 38 potential participants
including:
• fourteen policy makers at the national level who were
the most senior administrators at the Ministry of Public
Health (MOPH) and National Health Security Office
(NHSO), which is an autonomous health care institution
in Thailand that manages the Universal Health Coverage
scheme;
￿ five hospital directors who are responsible for allocat-
ing resources within Thai healthcare institutions;
￿ twelve health professionals (medical specialists) who
are responsible for resource allocation decisions at the
patient-level, and;
￿ seven academics  who produce and/or use economic
evaluation information to inform decision makers.
For policy makers at national level letters were sent to the
top seven senior administrators at the MOPH, both poli-
ticians and bureaucrats, and the top seven senior admin-
istrators of the NHSO. For the hospital directors, the five
directors of the public hospitals where the authors had
previously conducted the aforementioned economic eval-
uation studies[19,20] were invited for interview. The invi-
tation letters were also purposively sent to health
professionals at those five public hospitals. It was an
intention to cover a wide range of medical specialistsBMC Health Services Research 2008, 8:197 http://www.biomedcentral.com/1472-6963/8/197
Page 3 of 9
(page number not for citation purposes)
including two internists, two surgeons, two nephrologists,
two paediatricians, one oncologist, one ophthalmologist,
one orthopaedist and one otorhinolaryngologist. Finally,
seven Thai academics whose names were identified from
national and international publications on issues of
'health care rationing/prioritisation' were invited to par-
ticipate in the study.
Thirty-six respondents agreed to participate and were
interviewed between December 2004 and May 2005
(missing two health professionals, paediatrician and
orthopaedist). They were predominantly male (only two
were female physicians), had an average age of 50 years
and 34 out of 36 (94%) had a medical background (only
two academics not qualified in medicines), which reflects
the composition of senior management in the health sec-
tor in Thailand more generally. Only two policy makers
and four academics had formal training in health eco-
nomics or health care financing.
Interview schedule
At the beginning of the interview every respondent was
given a brief introduction to health economic evaluation,
including the concepts and applications of QALY maxim-
isation. The semi-structured interview schedule then had
two related parts. The first was a set of questions to explore
policy actors' opinions about existing criteria for includ-
ing health interventions in the UC benefit package, and
their acceptance and values relating to the use of eco-
nomic evaluation for development of the benefit package.
The findings from these general questions are presented
elsewhere[26].
The second part of the interview consisted of a hypotheti-
cal decision-making case scenario in which respondents
were presented with a choice of two interventions and
asked to decide which one to include in the UC package,
based on different types of evidence, including the eco-
nomic evaluation data collected as part of the wider
research project. They were given a scenario in which the
government was considering inclusion of one of two treat-
ments, (1) laparoscopic cholecystectomy (LC) for gall-
bladder disease, versus (2) dialysis for chronic renal
disease. The data presented to the respondents came from
the results of economic evaluation studies conducted by
the first author[19,20].
The selection of the two interventions for the case scenario
was based on several important factors. Firstly, it was
important to make the hypothetical scenario as realistic as
possible, and both these treatments were the subject of
real public debate at the time of the study. There was and
continues to be pressure from various interest groups to
include dialysis for chronic renal disease and laparoscopic
surgery in the UC benefit package[27]. Neither LC nor
dialysis were covered by the UC at the time of the inter-
view, although conventional open cholecystectomy (OC)
for gallbladder disease and palliative management for
chronic renal disease were included. LC and dialysis were
both being offered by other public health insurance
schemes at the time.
Secondly, the two interventions were selected because
they have several features, identified from the literature,
which were likely to highlight conflicting priorities
towards the allocation of health care resources (see Table
1), and so stimulate discussion about the application of
economic evaluation in real world decision-making, for
example whether life saving interventions should be pri-
oritised over cost effective interventions, and how to deal
with questions of equitable resource allocation or protec-
tion against catastrophic health care payments[28].
In order to assess the relative importance given by
respondents to a particular type of information or evi-
dence (disease severity and treatment alternatives, cost
effectiveness, budget impacts) the information was delib-
erately not presented at once but arranged into three
staged components. Each piece of information was
revealed separately and between each presentation the
respondent was asked to choose the intervention that they
would support to be included in the UC package. In addi-
tion, the interviewer did not inform respondents that
there would be more information available after present-
ing the first and then the second piece of information.
The first piece of information described the two treat-
ments and the expected recovery rates or quality of life
resulting from the treatment [see additional file 1]. The
second piece of information described the cost utility
ratios of the two interventions, to see if this information
changed the respondent's decision to choose between LC
for gallbladder disease or dialysis for chronic renal disease
[see additional file 2]. Finally, the overall financial
impacts for the government and patients were presented
[see additional file 3]. It was expected that the financial
implications for both public and private sectors would
have a greater influence on the respondent's decision than
economic evaluation information, so these financial
implications were presented last.
After each piece of information was presented, a struc-
tured question was asked to elicit a specific decision-mak-
ing response. To encourage a response to the case scenario
the interviewer stressed that there were no right or wrong
answers. Although the respondents could refuse to make
a choice, this option was not openly expressed to them so
the refusal to make a choice was accepted only on request.
Following the structured choice question, respondentsBMC Health Services Research 2008, 8:197 http://www.biomedcentral.com/1472-6963/8/197
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were then encouraged to discuss and explain their deci-
sions using open question formats.
Analysis
All interviews were recorded on audiotape and transcribed
verbatim. The first author read all the Thai transcripts and
developed a list of codes (or themes) and sub-codes that
were derived from respondents' understanding and rea-
soning behind their choices. One of our interests was to
explore whether the respondents' different positions and
duties influenced their attitudes and acceptance of using
economic evaluation as a tool for healthcare rationing.
The analysis also consisted of simple descriptive statistics
(absolute counts and percentages) to describe policy
actors' choices.
Results
The distribution of responses to the three pieces of infor-
mation is shown in [see Figure 1]. Given the first informa-
tion set about disease severity and treatment, 58% of
respondents, including eight decision makers at national
level, three hospital directors, seven health professionals
and three academics opted to support the life-saving inter-
vention, dialysis for chronic renal disease, rather than LC
for gallbladder disease. The most common explanation
from the supporters was that dialysis was a life-saving
intervention, whereas LC was not life saving and without
LC conventional open surgery was still effective and avail-
able to patients.
One academic respondent supported dialysis on the
grounds that including it in the UC benefit package would
reduce an inequality of access in the Thai health care sys-
tem:
"I preferred dialysis because at present all health insur-
ance schemes except the UC provide dialysis to their
beneficiaries" (academic).
A small group (one decision maker at national level, one
hospital director and three health professionals) chose to
reject dialysis and support LC, but mainly for reasons
other than cost-effectiveness. The one policy maker
believed that dialysis would not be a cost-effective option
while the hospital director and the three health profes-
sionals believed that there would not be adequate finan-
cial or human resources, for example nephrologists and
dialysis nurses to provide adequate dialysis, if the UC
included it within the benefit package:
"The government can spend money to buy dialysis
machines right now as much as they want but they
can't buy hundreds of nephrologists and nurses over
night" (hospital director).
Five decision makers at the national level, one hospital
director and four academics refused to make a choice at
this stage and asked for more information on cost-effec-
tiveness.
Table 1: Comparison of characteristics of laparoscopic cholecystectomy (LC) and renal dialysis used in the case scenario.
Severity of disease and 
importance of the 
intervention: are there 
alternatives?
Equity of access 
improvement
Cost-effectiveness based 
on economic evaluation*
Financial impact on 
government budget
++ + + + +-
LC for gallbladder 
disease
Medical treatment and open 
conventional (OC) surgery 
are both available.
13% of patients in the 
country undergoing LC are 
under UC but have to pay a 
proportion of the cost. An 
alternative (OC) is available 
without a charge.
Compared to open surgery, 
the incremental cost-
effectiveness ratio (ICER) 
for LC is less than 1 Thai 
GDP per capita and so 
considered cost-effective.
Relatively very small budget 
needed if it is to be included 
in the UC package. If 
included the indirect and 
direct non medical costs to 
households would also be 
reduced substantially.
+++ +++ - +++
Dialysis for end-stage 
renal disease
The availability of kidney 
donors is very limited. 
Without dialysis or kidney 
transplantation patients will 
die within 3–6 months.
Less than 5% of patients 
undergoing dialysis are 
under UC and have to pay 
the full cost. There is no 
alternative available for 
them.
Compared to 'palliative 
care', ICER for dialysis is 
higher than 5 times Thai 
GDP per capita and so 
considered non cost-
effective.
Very huge financial impact 
on the overall UC budget.
*A report from the Commission on Macroeconomics and Health suggests the use of a threshold three times that of Gross Domestic Product (GDP) 
per capita as a basis for interpreting whether an intervention is cost-effective and should be adopted as a health technology in developing countries 
[32].
Marks: +++ "very high", ++ "high", +"moderate", – "none".BMC Health Services Research 2008, 8:197 http://www.biomedcentral.com/1472-6963/8/197
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When the second information set was provided (eco-
nomic evaluation findings), five respondents shifted to
the LC (Figure 1). One policy maker at the national level
shifted support from dialysis to LC and explained:
"If I was looking at an individual patient I would
choose dialysis, but I am currently making this deci-
sion for society as a whole and evidence shows that LC
is a better choice" (national policy maker).
The other four who shifted their support to LC came from
the group of ten who had previously not made a decision
(two policy makers, one hospital director and one aca-
demic). They argued that the economic evaluation data
were good enough to justify support of LC:
"If these figures are right, it's clear that dialysis is cost-
ineffective so I would not support it" (academic).
One policy actor, a health professional, moved from sup-
porting dialysis to a no response after hearing the cost-
effectiveness information and explained that her decision
was based on confusion:
"I know it [dialysis] is very important for patients with
renal disease but your data make me feel that it may be
too expensive to extend their life. I am now confused
and not sure whether to support either" (health pro-
fessional).
Despite the cost effectiveness information being pre-
sented, however, about half of the respondents (19 or
53%) continued to support dialysis. Most of them felt that
in this particular situation it was ethically wrong not to
support dialysis that could save a number of lives:
"In my view, your choices (LC versus dialysis) are
incomparable.... Even if the treatment proves to be
cost-ineffective, not covering it might create the
impression that critically ill patients are being aban-
doned" (national policy maker, senior administrator
of NHSO).
Three decision makers at the national level also thought
that the coverage decision should be made not only on
theoretical and empirical grounds but importantly it
should also make sense and be acceptable to the general
Distribution of choices by type of respondent after three sets of case scenario information were presented sequentially Figure 1
Distribution of choices by type of respondent after three sets of case scenario information were presented 
sequentially.
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public. Since any decision made by them would be
announced to the public they argued that it should be
politically defensible. In this case, they thought that it was
unacceptable to let patients with chronic renal disease die
without offering proven effective treatment. They felt that
because dialysis was a life-saving intervention, the general
public would opt to support it over LC and so they would
also like to do so:
"If the UC announces to the public that it will include
LC in the benefit package, I think that it will not be
appreciated by many people. But if the UC is about to
cover dialysis, it will be very much different" (national
policy maker).
The decision shift away from dialysis to LC was most dra-
matic after the third information set was presented: the
global budget impact of their decision. Three respondents
shifted from a no response situation to LC (one policy
maker at national level, one academic and one health pro-
fessional), and two shifted from dialysis to LC (one policy
maker at national level and one hospital director). Both of
the latter explained they were now aware that the total
cost of their decision to support dialysis was too expensive
for the Thai healthcare system and that the government
budget was too limited for dialysis in the long run.
After all three pieces of information had been presented
more respondents (n = 17) still supported dialysis over LC
(n = 15), despite LC's higher cost effectiveness. Four
respondents still refused to make a choice for several rea-
sons: both choices were not attractive and some alterna-
tive options were needed; the public should play a part in
making this tough decision; and there was still not
enough information to make a decision, for example the
lack of cost-utility information for a range of potential
interventions that needed to be considered at the same
time:
"We can't consider only two interventions. Theoreti-
cally, we need to compare altogether all interventions
that are in and out of the package since we may find
some interventions outside the package that are more
cost-effective than these two" (academic).
Discussion
Cost-utility analysis is well accepted amongst health econ-
omists, given the number of publications in academic
journals[29], but little is known about how policy makers
and health professionals perceive and value its findings
and whether such evidence is meaningful to them and rel-
evant to the decisions they take[30]. The present study
qualitatively illustrated how different health policy actors
react to decision-making dilemmas about resource alloca-
tion, for example whether to give priority to cost-effective
non-life saving interventions, or cost-ineffective life sav-
ing interventions.
The data presented on policy actors' responses when faced
with a hypothetical but realistic decision confirms that
health care policy actors saw limits to the usefulness of
economic evaluation (cost-utility analysis)[31]. Twenty
six out of 36 (72%) respondents were not convinced by
the presentation of economic evaluation findings and
chose not to support the inclusion of a proven cost-effec-
tive intervention in the UC benefit package. Even the
majority of academics supported renal dialysis due to eth-
ical or equity concerns. Indeed, there were only six
respondents, including three policy makers at national
level, one hospital director, one health professional and
one academic, (6/36, 17%) whose decisions were influ-
enced by economic evaluation evidence.
It seems reasonable to conclude that economic evaluation
does not deal with many important factors or priorities
that concern decision makers when they are making
rationing decisions:
￿ ethical concerns relating to questions of saving life or
equity;
￿ the availability and accessibility of treatment alterna-
tives;
￿ awareness of the feasibility of policy options including
availability of human and financial resources;
￿ organizational allegiances and institutionalised prac-
tices such as the primacy of the right to treatment;
￿ concerns about power over decision-making and wider
political pressure on policy makers[31].
The findings presented in this paper add substance to and
illuminate these complexities and difficulties. One of the
most obvious difficulties is that economic evaluation
ignores alternative ethical values that can be held by pol-
icy actors. More respondents, for example, decided that it
was ethically right to prioritise a life-saving cost-ineffec-
tive intervention, dialysis, over a non-life saving cost-
effective intervention, LC. This ethical preference clearly
conflicts with economic evaluation, which is founded on
a health maximisation philosophy, and echoes well-
founded ethical positions that point to the importance of
helping the neediest as the basis of philosophical jus-
tice[28,32,33]. Policy actors who prioritised severely ill
candidates ahead of others, even though their treatment
was less cost-effective, also argued that the majority of the
public would have the same ethical values and expecta-
tions for healthcare rationing. In other settings studiesBMC Health Services Research 2008, 8:197 http://www.biomedcentral.com/1472-6963/8/197
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have explored public preferences towards the use of the
QALY maximisation rule, and found that the general pub-
lic's view does not always support maximising the
number of QALYs gained[33]. People were willing to pri-
oritise resource allocation to severely ill patients, even
when they would benefit less from treatment than others,
or were willing to reduce the number of QALYs gained in
order to help those perceived to be most in need in terms
of severity of illness.
Policy makers' concern about the public's support for
QALY maximisation highlights the political factors that
influenced coverage decisions in the case scenario. Among
decision makers at the national level, despite their
expressed concern about resource constraints and the
need for efficiency, not all supported the cost-effective LC
intervention because they were aware of the importance
of gaining public support and acceptance of their deci-
sion. Their career paths are, to some extent, dependent on
their ability to justify and defend their decisions politi-
cally and gain public acceptance.
Hospital directors, in contrast, had fewer concerns about
public perceptions and by the end of the interview the
majority (3/5, 60%) had rejected dialysis and supported
LC. However the support for LC from two of these three
directors was based on overall resource constraints rather
than on the health maximising concept of economic eval-
uation, reflecting their responsibility for the management
of the hospital's financial and human resources to deliver
services.
Health professionals' are trained and operate within an
institutional environment that means in principle they act
in the best interest of the patient, so they are likely to pri-
oritise patient care over economic considerations. This
helps to explain why the majority (6/10) continued to
support dialysis after the presentation of economic evalu-
ation information. The majority of health professionals
were more concerned about saving lives, even when the
opportunity cost was a reduction in the quality of life of
other individuals in need. This decision perhaps reflects
the fact that health professionals' overriding professional
responsibility is to the particular patient under considera-
tion[34], and that they make decisions for individuals
with less recourse to wider societal perspectives than the
national policy makers.
Even in the case of academics trained in economic evalu-
ation, more did not support the use of economic evalua-
tion for prioritising healthcare than did. While they
argued that improved efficiency through the use of eco-
nomic evaluation was important they also stressed that
this criterion needed to be balanced against equity and
affordability. This illustrates the fact that the non-use or
selective use of economic evaluation will not simply be
resolved by providing appropriate education of informa-
tion but incorporate various competing decision making
priorities in order to gain widespread acceptance in the
priority setting process.
It is important to note two possible limitations of these
findings. First, the data on policy actors' decisions are
based on a hypothetical scenario and in a real world sce-
nario the decisions made may well have been different.
For example in Thailand decision makers might look at
just one intervention such as dialysis and consider afford-
ability and cost-effectiveness, but not make comparisons
across health problems. However, the scenario presented
was a topical and realistic one. All the information pro-
vided, including the economic evaluation data and finan-
cial implications, were based on real studies and the case
of dialysis was one of public debate at the time of the
interviews because the government was considering its
inclusion in the UC benefit package[35]. During the inter-
views it was evident that the respondents took the ques-
tions very seriously. Hence the decisions made in the
hypothetical situation may, in fact, reflect the real prefer-
ences of respondents if they had been taking part in a real
policy decision.
Second, this study was not undertaken to produce 'gener-
alisable results' about how economic evaluation might be
accepted or used in other settings. Decision makers else-
where may attach more or less weight to different resource
allocation criteria, and the same health technology may
have different characteristics where it is offered in other
settings. Also, it is not possible to generalise the findings
from this study to all policy makers in Thailand. However,
the qualitative design aimed to offer in-depth understand-
ing about the complexity of decision-making in a specific
context which can still be informative for analysts else-
where.
Conclusion
The policy actors' perspectives and positions, presented in
this and a related paper[31] have highlighted several diffi-
culties and dilemmas for the introduction of economic
evaluation into health technology coverage decision mak-
ing processes in Thailand. There was a lack of consensus
between and within different groups of health care policy
actors on the best criteria for allocating scarce health care
resources. However, interpreting the data on policy actors'
different priorities and decisions, and the rationales
behind them, it is possible to better understand the differ-
ent priorities of policy actors and so inform better proce-
dures for or management of a complex and unavoidable
rationing process in healthcare.BMC Health Services Research 2008, 8:197 http://www.biomedcentral.com/1472-6963/8/197
Page 8 of 9
(page number not for citation purposes)
Increasing the use of economic evaluation in Thailand, to
make health technology resource allocation decisions
more explicit and transparent, requires a search for how
best to incorporate the tool within existing and competing
decision making priorities. Otherwise, economic evalua-
tion which is based mainly on a concept of 'the greatest
happiness of the greatest number' would fail to provide a
guide for making rational resource allocation in most
cases.
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